Abstract
We adopted the reverse transcriptase - loop mediated isothermal amplification (RT-LAMP) to detect SARS-Cov-2 in patient samples. Two primer sets for genes N and Orf1ab were designed to detect SARS-CoV-2, and one primer set was designed to detect the human gene Actin. We collected prospective 138 nasopharyngeal swabs, 70 oropharyngeal swabs, 69 saliva, and 68 mouth saline wash samples from patients suspected to have severe acute respiratory syndrome (SARS) caused by SARS-CoV-2 to test the RT-LAMP in comparison with the golden standard technique RT-qPCR. Accuracy of diagnosis using both primers, N5 and Orf9, was evaluated. Sensitivity and specificity for diagnosis was 96% (95% CI 87-99) and 85% (95% CI 76-91) in 138 samples, respectively. Accurate diagnosis results were obtained only in nasopharyngeal swab processed via extraction kit. Accurate and rapid diagnosis could aid COVID-19 pandemic management by identifying, isolating, and treating patients rapidly.
Highlights
New nucleic acid amplification test for the diagnosis of SARS-CoV-2 using the RT-LAMP
N5 primer set showed mutations in strains of interest, such as the gamma strain (P.1) of SARS-CoV-2
When evaluated in combination N5 and Orf9 primer sets maintained high sensitivity and specificity
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [grant number 403548/2020-9] and Coordenacao de Aperfeicoamento Pessoal de Nivel Superior - Programa Institucional de Internacionalizacao (CAPES-PRINT) [grant number 88887.593075/2020-00].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This proposal was approved by the National Ethical Review Board on 06/10/2020 with the code CAAE 33460220.7.0000.5045. Data collected from the research participants were kept confidential.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- COVID-19
- coronavirus disease 2019
- FBS
- fetal bovine serum
- HMPV
- human metapneumovirus
- NAAT
- nucleic acid amplification test
- RT-LAMP
- reverse transcription loop-mediated isothermal amplification
- PBS
- phosphate-buffered saline
- RT-qPCR
- quantitative reverse transcription-polymerase chain reaction
- RV-16
- rhinovirus serotype 16
- SARS-CoV-2
- severe acute respiratory syndrome-coronavirus 2
- TCID50
- median tissue culture infective dose
- TPCK
- tosylsulfonyl phenylalanyl chloromethyl ketone
